Differential Expression of HSP90β in MDA-MB-231 and MCF-7 Cell Lines after Treatment with Doxorubicin |
Jokar, Fereshte
(Anatomical Sciences Research Center, Kashan University of Medical sciences)
Mahabadi, Javad Amini (Gametogenesis Research Center, Kashan University of Medical Sciences) Salimian, Morteza (Platelet Research Laboratory, Kashan University of Medical Science) Taherian, Aliakbar (Anatomical Sciences Research Center, Kashan University of Medical sciences) Hayat, Seyyed Mohammad Gheibi (Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences) Sahebkar, Amirhossein (Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences) Atlasi, Mohammad Ali (Anatomical Sciences Research Center, Kashan University of Medical sciences) |
1 | Song CH, et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Research. 2010;12(2):R20. DOI |
2 | Huang B, et al. Differential expression of estrogen receptor , , and in lobular and ductal breast cancer. Proceedings of the National Academy of Sciences. 2014;111(5):1933-1938. DOI |
3 | Barrios C, et al. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Annals of oncology. 2009;20(7):1157-1162. DOI |
4 | Taherian A, Mazoochi T. Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. Iran J Basic Med Sci. 2012;15(1):669-77. |
5 | Taherian A, Krone PH, Ovsenek N. A comparison of and interactions with cochaperones and substrates. Biochemistry and Cell Biology. 2008;86(1):37-45. DOI |
6 | Didelot C, et al. Interaction of heat-shock protein isoform () with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death Differ. 2008;15(5):859-66. DOI |
7 | Dong H, et al. Breast cancer MDA-MB-231 cells use secreted heat shock protein-90alpha () to survive a hostile hypoxic environment. Scientific reports. 2016;6. |
8 | Romaniuk A, Lyndin M. Immune microenvironment as a factor of breast cancer progression. Diagnostic pathology. 2015;10(1):79. DOI |
9 | Veronesi U, et al. Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. The breast journal. 2009;15(3):291-295. DOI |
10 | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5-29. DOI |
11 | Longley D, Johnston P. Molecular mechanisms of drug resistance. The Journal of pathology. 2005;205(2):275-292. DOI |
12 | Aas T, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature medicine. 1996;2(7):811-814. DOI |
13 | Echeverria PC, et al. Detection of changes in gene regulatory patterns, elicited by perturbations of the Hsp90 molecular chaperone complex, by visualizing multiple experiments with an animation. BioData Min. 2011;4(1):15. DOI |
14 | Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncologica. 1992;31(2):205-213. DOI |
15 | Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell. 2002;111(7):923-925. DOI |
16 | Joly AL, et al. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. Journal of Innate Immunity. 2009;2(3):238-247. DOI |
17 | Hickey E, et al. Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein. Mol Cell Biol. 1989;9(6):2615-26. DOI |
18 | Rebbe NF, et al. Nucleotide sequence and regulation of a human 90-kDa heat shock protein gene. Journal of Biological Chemistry. 1989;264(25):15006-15011. DOI |
19 | Neve RM, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer cell. 2006;10(6):515-527. DOI |
20 | Chin K, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer cell. 2006;10(6):529-541. DOI |
21 | Hollestelle A, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast cancer research and treatment. 2010;121(1):53-64. DOI |
22 | Kao J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PloS one. 2009;4(7):e6146. DOI |
23 | Wood AJ, Osborne CK. Tamoxifen in the treatment of breast cancer. New England Journal of Medicine. 1998;339(22):1609-1618. DOI |
24 | Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast cancer research and treatment. 2004;83(3):249-289. DOI |
25 | Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nature Reviews Cancer. 2007;7(9):659-672. DOI |
26 | Soule H, et al. A human cell line from a pleural effusion derived from a breast carcinoma. Journal of the National Cancer Institute. 1973;51(5):1409-1416. DOI |
27 | Fabbro D, et al. Epidermal growth factor binding and protein kinase C activities in human breast cancer cell lines: possible quantitative relationship. Cancer research. 1986;46(6):2720-2725. |
28 | Prat A, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. DOI |
29 | Heiser LM, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences. 2012;109(8):2724-2729. DOI |
30 | Visagie M, Mqoco T, Joubert A. Sulphamoylated estradiol analogue induces antiproliferative activity and apoptosis in breast cell lines. Cellular and Molecular Biology Letters. 2012;17(4):549-558. DOI |
31 | Georgakis GV, et al. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol. 2006;34(12):1670-9. DOI |
32 | Soti C, et al. Heat shock proteins as emerging therapeutic targets. British journal of pharmacology. 2005;146(6):769-780. DOI |
33 | Lebret T, et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90. Cancer. 2003;98(5):970-977. DOI |
34 | Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA: a cancer journal for clinicians. 2005;55(3):178-194. DOI |
35 | Ullah MF. Sulforaphane (SFN): an isothiocyanate in a cancer chemoprevention paradigm. Medicines. 2015;2(3):141-156. DOI |
36 | Qazi A, et al. Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol. 2010;3(6):389-99. DOI |
37 | Beyer-Sehlmeyer G, et al. Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin. Eur J Cancer. 1999;35(12):1735-42. DOI |
38 | Bertram J, et al. Overexpression of ribosomal proteins L4 and L5 and the putative alternative elongation factor PTI-1 in the doxorubicin resistant human colon cancer cell line LoVoDxR. Eur J Cancer. 1998;34(5):731-6. DOI |
39 | Zhang W, et al. Expressions of heat shock protein (HSP) family HSP 60, 70 and 90 a in colorectal cancer tissues and their correlations to pathohistological characteristics. Chinese J Cancer. 2009;28:1-7. |
40 | Lim SO, et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World journal of gastroenterology: WJG. 2005;11(14):2072-2079. DOI |
41 | Yano M, et al. Expression and roles of heat shock proteins in human breast cancer. Cancer Science. 1996;87(9):908-915. DOI |
42 | Guo W, et al. Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma. PloS one. 2014;9(1):e85766. DOI |